Limin Liu1,2, Herui Wang2, Jing Cui2, Qi Zhang2, Wei Zhang2, Wanlin Xu1, Hao Lu1, Shengwen Liu1, Shukun Shen1, Francia Fang3, Lei Li1, Wenjun Yang1, Zhengping Zhuang2, Jiang Li1. 1. Department of Oral Pathology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, National Clinical Research Center for Oral Diseases, Shanghai, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China. 2. Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 3. Duke University, Durham, North Carolina, USA.
Abstract
BACKGROUND/AIMS: Protein phosphatase 2A (PP2A) is a ubiquitous serine/threonine phosphatase that mediates cell cycle regulation and metabolism. Mounting evidence has indicated that PP2A inhibition exhibits considerable anticancer potency in multiple types of human cancers. However, the efficacy of PP2A inhibition remains unexplored in mucoepidermoid carcinoma (MEC), especially in locally advanced and metastatic cases with limited systemic treatment. In this study, we demonstrated the therapeutic potency of LB100 in mucoepidermoid carcinoma. METHODS: In this study, the expression of PP2A was evaluated using immunohistochemical (IHC) staining. The effects associated with LB100 alone and in combination with cisplatin for the treatment of mucoepidermoid carcinoma were investigated both in vitro, regarding metabolism, proliferation, and migration, and in vivo in a mucoepidermoid carcinoma xenograft model. In addition, with LB100 treatment and in response to an insulin stimulus, the expression levels and phosphorylation levels of targets in the PI3K-AKT pathway were determined using western blot analysis and immunoblotting. RESULTS: The expression of protein phosphatase 2A was significantly upregulated in the clinical specimens of high-grade MECs compared with those of low-/medium-grade MECs and normal controls. In this article, we report that a small molecule PP2A inhibitor, LB100, decreased cellular viability and glycolytic activity and induced G2/M cell cycle arrest. Importantly, LB100 enhanced the efficacy of cisplatin in mucoepidermoid carcinoma cells both in vitro and in vivo. PP2A inhibition by LB100 increased the phosphorylation of insulin receptor substrate 1(IRS-1) on serine residues, downregulated the expression of phosphatidylinositol 3-kinase (PI3K) p110 alpha subunit and dephosphorylated AKT at Ser473 and Thr308 in mucoepidermoid carcinoma cells in response to insulin stimulus. CONCLUSION: These results highlight the translational potential of PP2A inhibition to synergize with cisplatin in mucoepidermoid carcinoma treatment.
BACKGROUND/AIMS: Protein phosphatase 2A (PP2A) is a ubiquitous serine/threonine phosphatase that mediates cell cycle regulation and metabolism. Mounting evidence has indicated that PP2A inhibition exhibits considerable anticancer potency in multiple types of humancancers. However, the efficacy of PP2A inhibition remains unexplored in mucoepidermoid carcinoma (MEC), especially in locally advanced and metastatic cases with limited systemic treatment. In this study, we demonstrated the therapeutic potency of LB100 in mucoepidermoid carcinoma. METHODS: In this study, the expression of PP2A was evaluated using immunohistochemical (IHC) staining. The effects associated with LB100 alone and in combination with cisplatin for the treatment of mucoepidermoid carcinoma were investigated both in vitro, regarding metabolism, proliferation, and migration, and in vivo in a mucoepidermoid carcinoma xenograft model. In addition, with LB100 treatment and in response to an insulin stimulus, the expression levels and phosphorylation levels of targets in the PI3K-AKT pathway were determined using western blot analysis and immunoblotting. RESULTS: The expression of protein phosphatase 2A was significantly upregulated in the clinical specimens of high-grade MECs compared with those of low-/medium-grade MECs and normal controls. In this article, we report that a small molecule PP2A inhibitor, LB100, decreased cellular viability and glycolytic activity and induced G2/M cell cycle arrest. Importantly, LB100 enhanced the efficacy of cisplatin in mucoepidermoid carcinoma cells both in vitro and in vivo. PP2A inhibition by LB100 increased the phosphorylation of insulin receptor substrate 1(IRS-1) on serine residues, downregulated the expression of phosphatidylinositol 3-kinase (PI3K) p110 alpha subunit and dephosphorylated AKT at Ser473 and Thr308 in mucoepidermoid carcinoma cells in response to insulin stimulus. CONCLUSION: These results highlight the translational potential of PP2A inhibition to synergize with cisplatin in mucoepidermoid carcinoma treatment.
Authors: Ira K Gordon; Jie Lu; Christian A Graves; Kristin Huntoon; Jason M Frerich; Ryan H Hanson; Xiaoping Wang; Christopher S Hong; Winson Ho; Michael J Feldman; Barbara Ikejiri; Kheem Bisht; Xiaoyuan S Chen; Anita Tandle; Chunzhang Yang; W Tristram Arscott; Donald Ye; John D Heiss; Russell R Lonser; Kevin Camphausen; Zhengping Zhuang Journal: Mol Cancer Ther Date: 2015-05-04 Impact factor: 6.261
Authors: François H T Duong; Michael T Dill; Matthias S Matter; Zuzanna Makowska; Diego Calabrese; Tanja Dietsche; Sylvia Ketterer; Luigi Terracciano; Markus H Heim Journal: Carcinogenesis Date: 2013-07-29 Impact factor: 4.944
Authors: Ki-Eun Chang; Bih-Rong Wei; James P Madigan; Matthew D Hall; R Mark Simpson; Zhengping Zhuang; Michael M Gottesman Journal: Mol Cancer Ther Date: 2014-11-05 Impact factor: 6.261
Authors: Vincent Chung; Aaron S Mansfield; Fadi Braiteh; Donald Richards; Henry Durivage; Richard S Ungerleider; Francis Johnson; John S Kovach Journal: Clin Cancer Res Date: 2016-12-30 Impact factor: 12.531
Authors: Yonara Maria Freire Soares Marques; Marina de Deus Moura de Lima; Sérgio de Melo de Melo Alves; Fernando Augusto Soares; Vera Cavalcanti de Araújo; Décio dos Santos Pinto; Andrea Mantesso Journal: Oral Oncol Date: 2008-05-15 Impact factor: 5.337
Authors: Victoria L B Nelson; Ya-Ping Jiang; Kathleen G Dickman; Lisa M Ballou; Richard Z Lin Journal: Am J Physiol Endocrinol Metab Date: 2014-04-01 Impact factor: 4.310
Authors: Scott Frendo-Cumbo; Taoyingnan Li; Dustin A Ammendolia; Etienne Coyaud; Estelle M N Laurent; Yuan Liu; Philip J Bilan; Gordon Polevoy; Brian Raught; Julie A Brill; Amira Klip; John H Brumell Journal: iScience Date: 2022-09-24
Authors: Tamara Mirzapoiazova; Gang Xiao; Bolot Mambetsariev; Mohd W Nasser; Emily Miaou; Sharad S Singhal; Saumya Srivastava; Isa Mambetsariev; Michael S Nelson; Arin Nam; Amita Behal; Leonidas Arvanitis; Pranita Atri; Markus Muschen; François L H Tissot; James Miser; John S Kovach; Martin Sattler; Surinder K Batra; Prakash Kulkarni; Ravi Salgia Journal: Mol Cancer Ther Date: 2021-07-12 Impact factor: 6.261